RxDoctor Payments Data

David Woods, MD

Ophthalmology · Chico, CANPI 1225038185

Payments from drug & device makers

$366,924in general payments, 2019–2025

Across 289 payments — averaging $1269.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$358K
  • Ivantis, Inc$4K
  • NEW World Medical,inc.$2K
  • Alcon Research LLC$2K
  • Alcon$437
  • AbbVie$223
  • plus $752 from 11 others
$9,402in research payments, 2019–2025

Across 39 payments — averaging $241.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$9K

What the payments were for

  • Consulting fees$95,72496%
  • Speaking & faculty fees$580%
  • Food & beverage$3,8294%
  • Gifts$1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$366,924 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$1,180,613
Medicare patients
1,994
Services billed
6,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost253$106,391
RhopressaNetarsudil Mesylate154$82,517
XiidraLifitegrast58$43,451
RocklatanNetarsudil Mesylat/Latanoprost60$27,706
Prednisolone Acetate893$24,890
Travoprost52$11,517
Latanoprost1,246$10,544
Ketorolac Tromethamine688$9,779
Alphagan PBrimonidine Tartrate30$9,495
IlevroNepafenac12$8,334
VyzultaLatanoprostene Bunod33$8,184
Cyclosporine21$6,259
Timolol Maleate659$6,218
Brimonidine Tartrate230$6,129
ProlensaBromfenac Sodium13$4,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$223$119,647295 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$180$110,223214 claims
NovartisIlevro$129$8,33412 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$24$4,40513 claims
AlconSimbrinza$437$4,24321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →